Evidence map›Paper›PMID 36397951›Full record

ArticleCanadian journal of gastroenterology & hepatology2022

The Role of Combining Probiotics in Preventing and Controlling Inflammation: A Focus on the Anti-Inflammatory and Immunomodulatory Effects of Probiotics in an

Shadi Aghamohammad, Amin Sepehr, Seyedeh Tina Miri, Saeideh Najafi, Mohammad R Pourshafie, Mahdi Rohani

Open access · goldAbstract read
In one paragraph

Article in Canadian journal of gastroenterology & hepatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. The interplay between probiotics and mast cells in gut inflammation: a mini-review.Frontiers in cellular and infection microbiology · 2026
    Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Application and Challenges of Using ProbioticDiseases (Basel, Switzerland) · 2025
    Review
  10. Article
  11. Microorganisms · 2025
    Article
  12. Review
  13. Review
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Shadi AghamohammadDepartment of Bacteriology, Pasteur Institute of Iran, Tehran, Iran.ORCID 0000-0003-1832-3695
Amin SepehrDepartment of Bacteriology, Pasteur Institute of Iran, Tehran, Iran.ORCID 0000-0001-6666-2005
Seyedeh Tina MiriDepartment of Biology, Science and Research Branch Islamic Azad University, Tehran, Iran.ORCID 0000-0002-0941-4432
Saeideh NajafiDepartment of Biology, Science and Research Branch Islamic Azad University, Tehran, Iran.ORCID 0000-0002-5520-5711
Mohammad R PourshafieDepartment of Bacteriology, Pasteur Institute of Iran, Tehran, Iran.ORCID 0000-0002-6226-7064
Mahdi RohaniDepartment of Bacteriology, Pasteur Institute of Iran, Tehran, Iran.ORCID 0000-0001-8956-5072
Pasteur Institute of Iran · IRIslamic Azad University, Science and Research Branch · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: IBD is an inflammatory disease with abnormalities such as dysbiosis and abnormal immune system activity. Probiotics, as live beneficial microorganisms, play a role in maintaining health through various mechanisms, including the modulation of the immune system and the control of inflammation. Here, we aimed to investigate the efficacy of a probiotic mixture of Method: A quantitative real-time polymerase chain reaction (qPCR) assay was conducted to analyze the expression of JAK/STAT and inflammatory genes after treatment with the probiotic mixture before, after, and simultaneously with the sonicated pathogen in the HT-29 cell line. The production of IL-6 and IL-1 Results: Treatment with probiotics resulted in downregulation of Conclusions: The probiotic mixture of

Indexed as

Inflammatory Bowel DiseasesProbioticsAnti-Inflammatory AgentsHumansInflammationInterleukin-6LactobacillusNF-kappa BAnti-Inflammatory AgentsInterleukin-6NF-kappa B

Identifiers

PMID36397951
PMCPMC9666007
OpenAlexW4308523687

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.